anti crt  (Bioss)

Journal: Oncology Letters

Article Title: Thrombospondin-1 triggers calreticulin expression in human mucoepidermoid carcinoma MC-3 cells via the PERK/CHOP pathway

doi: 10.3892/ol.2026.15589

Figure Lengend Snippet: TSP-1 promotes the translocation of CRT to the cell surface in MC-3 cells. Cells were stained with an APC-conjugated anti-CRT antibody, and CRT expression on the cell membrane is presented as mean fluorescence intensity. At the 72 h point: **P<0.01 vs. the control group; # P<0.05 vs. the TSP-1 group; and ▲ P<0.05 vs. the TSP-1 + ISRIB group. MFI, mean fluorescence intensity; CRT, calreticulin; TSP-1, thrombospondin-1.

Article Snippet: Primary antibodies, including anti-PERK (1:1,000; cat. no. MA8131; Abmart Pharmaceutical Technology Co., Ltd.), anti-CHOP (1:1,000; cat. no. WL00880; Wanleibio Co., Ltd.), anti-CRT (1:800; cat. no. bs-5913R; BIOSS) and anti-β-actin (1:5,000; cat. no. 66009-1-Ig; Proteintech Group Inc.), were diluted in 5% BSA and incubated with the membranes overnight at 4°C.

Techniques: Translocation Assay, Staining, Expressing, Membrane, Fluorescence, Control

Journal: Oncology Letters

Article Title: Thrombospondin-1 triggers calreticulin expression in human mucoepidermoid carcinoma MC-3 cells via the PERK/CHOP pathway

doi: 10.3892/ol.2026.15589

Figure Lengend Snippet: TSP-1 effects on cell surface CRT expression at 4 h. Cells were stained with an APC-conjugated anti-CRT antibody, and CRT expression on the cell membrane is presented as mean fluorescence intensity. At the 4 h time point. *P<0.05 compared with control group; # P<0.05 compared with TSP-1 action group; and ▲ P<0.05 compared with TSP-1 + ISRIB group. TSP-1, thrombospondin-1; CRT, calreticulin.

Article Snippet: Primary antibodies, including anti-PERK (1:1,000; cat. no. MA8131; Abmart Pharmaceutical Technology Co., Ltd.), anti-CHOP (1:1,000; cat. no. WL00880; Wanleibio Co., Ltd.), anti-CRT (1:800; cat. no. bs-5913R; BIOSS) and anti-β-actin (1:5,000; cat. no. 66009-1-Ig; Proteintech Group Inc.), were diluted in 5% BSA and incubated with the membranes overnight at 4°C.

Techniques: Expressing, Staining, Membrane, Fluorescence, Control

Journal: Materials Today Bio

Article Title: A precise theranostic nanoplatform amplifies anti-tumor efficacy via copper ionophores and sonodynamic therapy

doi: 10.1016/j.mtbio.2026.102957

Figure Lengend Snippet: The anti-tumor immune mechanism of ICCP NPs. a) Schematic illustration of cuproptosis mechanism. b) Immunofluorescence analysis of DLAT and FDX1 in 4T1 cells following various treatments. c) Schematic diagram illustrating the synergistic induction of ICD by SDT and cuproptosis. d) Immunofluorescence analysis of CRT and HMGB1 in 4T1 cells following various treatments. e) Quantitative analysis of CRT fluorescence intensity. f) ATP content in 4T1 cells following various treatments.

Article Snippet: Cells were then incubated overnight at 4 °C with primary rabbit polyclonal antibodies against DLAT (13426-1-AP, 1:200), FDX1 (12592-1-AP, 1:250), CRT (10292-1-AP, 1:200), and HMGB1 (10829-1-AP, 1:200) (Proteintech, Wuhan, China).

Techniques: Immunofluorescence, Fluorescence

Journal: Materials Today Bio

Article Title: A precise theranostic nanoplatform amplifies anti-tumor efficacy via copper ionophores and sonodynamic therapy

doi: 10.1016/j.mtbio.2026.102957

Figure Lengend Snippet: ICCP NPs mediated anti-tumor immunity in vivo . a) Schematic diagram llustrating the synergistic anti-tumor immune mechanism of ICCP NPs through SDT and cuproptosis. b) Immunofluorescence analysis of CRT and HMGB1 across different treatments. c) Assessment of mature DC proportions (CD80 + /CD86 + ) in tumor tissues via flow cytometry and d) corresponding quantitative analysis. e) Assessment of CD4 + T cells proportions in tumor tissues via flow cytometry and f) corresponding quantitative analysis. g) Assessment of CD8 + T cells proportions in tumor tissues via flow cytometry and h) corresponding quantitative analysis.

Article Snippet: Cells were then incubated overnight at 4 °C with primary rabbit polyclonal antibodies against DLAT (13426-1-AP, 1:200), FDX1 (12592-1-AP, 1:250), CRT (10292-1-AP, 1:200), and HMGB1 (10829-1-AP, 1:200) (Proteintech, Wuhan, China).

Techniques: In Vivo, Immunofluorescence, Flow Cytometry